Submitted as: Case ReportAuthors declare that the contents of this article are their own original unpublished findings.Title: Waldenström Macroglobulinemia Presenting a Subcutaneous Nodule as an Initial Skin Lesion: A Case ReportAuthors: Toshiyuki Sato¹, Michie Katsuta¹, Yoshimasa Nobeyama¹, Hideki Uryu2, Masaharu Kawashima2, Shingo Yano2, and Akihiko Asahina¹Affiliations: 1) Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan2) Division of Clinical Oncology / Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, JapanE-mail address: Toshiyuki Sato: sato-toshiyuki@jikei.ac.jp, Michie Katsuta: mkatta1219@gmail.com, Yoshimasa Nobeyama: nobederm@jikei.ac.jp, Hideki Uryu: uryu@jikei.ac.jp, Masaharu Kawashima: kawashimasa-k@jikei.ac.jp, Shingo Yano: yano@jikei.ac.jp, Akihiko Asahina: asahina-tky@umin.ac.jpCorresponding Author: Toshiyuki SatoDepartment of Dermatology, The Jikei University School of Medicine25-8 Nishi-Shimbashi 3-chome, Minato-ku, Tokyo 105-8461, JapanTEL: +81-3-3433-1111 Ext. 3857; FAX: +81-3-5401-0125E-mail address: sato-toshiyuki@jikei.ac.jpKeywords: Case report, Ibrutinib, Lymphoplasmacytic lymphoma, Nodule, Waldenström MacroglobulinemiaPotential conflicts of interest: The authors declare no conflicts of interest.Key Clinical Message: Cutaneous manifestations of Waldenström macroglobulinemia (WM), particularly subcutaneous nodules, are rare but easily biopsied, suggesting that subcutaneous lesions may contribute to diagnosis. Therefore, dermatologists need to understand the cutaneous manifestations of WM.Abstract: WM is a rare subtype of lymphoplasmacytic lymphoma characterized by bone marrow infiltration of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells. WM accounts for only 1-2% of hematological malignancies. Cutaneous involvement in WM is rare, with nodular lesions being even more uncommon. We reported a rare case with cutaneous nodular lesion as a clinical presentation of WM. A 65-year-old man presented with a subcutaneous nodule on the right upper arm. Nine years ago, he had been diagnosed with follicular lymphoma and treated with multiple therapies, including R-CHOP therapy, BR therapy, Bendamustine monotherapy, and R² regimen. Following R² regimen, a new lesion was detected on PET-CT. Physical and histopathological examinations revealed a dome-shaped nodule, which consisted of plasmacytoid lymphocytes and plasma cells positive for CD20 and CD138, but negative for CD10. A diagnosis of WM was made based on these findings. MYD88 L265P gene testing was not performed due to insurance limitations. The patient began treatment with ibrutinib, leading to a significant regression of the nodule. WM with cutaneous manifestations, particularly nodular lesions, is rare but important for dermatologists to recognize. Biopsy of subcutaneous lesions can aid in early diagnosis and treatment.Introduction: Waldenström macroglobulinemia (WM) is a rare subtype of lymphoplasmacytic lymphoma, accounting for only 1-2% of hematological malignancies [1-3]. It is characterized by bone marrow infiltration of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells, along with the presence of monoclonal immunoglobulin M (IgM) in the serum. According to the World Health Organization classification, a definitive diagnosis of WM requires evidence of bone marrow involvement by lymphoplasmacytic lymphoma and the detection of monoclonal IgM gammopathy, regardless of its concentration [3]. Although extramedullary involvement can occur in various organs, cutaneous manifestations are exceedingly rare, observed in only about 5% of cases [1]. These cutaneous lesions are typically classified into primary and secondary types, based on tumor cell infiltration or cryoglobulinemia [4]. In this report, we present a case of WM with rare subcutaneous nodular involvement, highlighting its significance in emphasizing the importance of recognizing this dermatological manifestation.Case history: A 65-year-old man was referred to us with a several months’ history of a subcutaneous nodule in the right upper arm. Left cervical lymphadenopathy was detected by a routine examination 9 years ago, he underwent lymph node biopsy and bone marrow examination. In the lymph node biopsy specimen, the normal lymph node architecture was lost, and a diffuse proliferation of small to medium-sized neoplastic lymphocytes were observed. The infiltrating cells were positive for CD20, CD79, and BCL2. In the bone marrow biopsy specimen, dense clusters of small to medium-sized neoplastic lymphocytes were observed and immunohistochemical analysis revealed strong positivity for CD20, CD79a, and BCL2, along with focal positivity for CD10. (Figure 1A and B). He was diagnosed with follicular lymphoma as a provisional diagnosis. He underwent R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin hydrochloride, oncovin, and prednisolone), BR therapy (bendamustine and rituximab), Bendamustine monotherapy, and R² regimen (lenalidomide and rituximab). Following R² regimen, a new lesion was detected in the right upper arm on PET-CT (standardized uptake value max: 3.37), leading to referral to our department (Figure 2A). No lytic lesions were observed on PET-CT. Physical examination showed no evidence of generalized fatigue, fever, or weight loss. A dome-shaped subcutaneous nodule, measuring 50 × 70 mm, was observed on the outer side of the right upper arm (Figure 2B). The complete blood cell count revealed white blood cell 3700 /μL (normal range, 3300-8600), hemoglobin 11.0 g/dL (normal range, 13.7-16.8), and blood platelet 135,000 /μL (normal range, 158,000-348,000). A biochemical blood test revealed a high β2-microglobulin level of 4.34 mg/L (normal range, 0.8-2.0), lactate dehydrogenase (LDH) level of 183 U/L (normal range, 124-222), albumin level of 3.8 g/dL (normal range, 4.1-5.1), creatinine level of 0.7 mg/dL (normal range, 0.65-1.07), calcium level of 8.9 mg/dL (normal range, 8.8-10.1) and high immunoglobulin M (IgM) level of 295 mg/dL (normal range, 33-183) which reached a maximum value of 321 mg/dL during the clinical course. Electrophoresis revealed a monoclonal peak of IgM-kappa type. We prioritized low-risk diagnostic procedures and performed a punch biopsy. Histopathological examination revealed dense clusters of small to medium-sized lymphocytes in the deep dermis, along with plasmacytoid neoplastic lymphocytes and plasma cells (Figure 3A and B). Infiltrating cells were positive for CD20, CD79a, and CD138, and negative for CD10 and a follicular dendritic cell meshwork positive for CD21 was not observed (Figure 4A, B and C). Immunohistochemistry showed kappa light chain was observed 3-fold more than lambda light chain (Figure 5A and B). On retrospective review of the initial bone marrow biopsy, infiltration by plasmacytoid lymphocytes and plasma cells was identified, and CD138 positivity was observed in these areas (Figure 1A and 6). Unfortunately, testing for the MYD88 L265P gene mutation is not covered by insurance, and therefore, has not been conducted in this case. Based on the presence of plasmacytoid lymphocytes, CD10 negativity in tumor cells, bone marrow infiltration of plasmacytoid lymphocytes, and monoclonal immunoglobulin M-kappa protein, a diagnosis of follicular lymphoma as a provisional diagnosis was changed to Waldenström macroglobulinemia.Methods (differential diagnosis) : WM is often described as challenging to differentiate from marginal zone lymphoma, plasmacytoma and IgM-type multiple myeloma. Marginal zone lymphoma is classified into extranodal marginal zone lymphoma (MALT lymphoma), nodal marginal zone lymphoma, and splenic marginal zone lymphoma. In the present case, the affected organs were bone marrow and skin. A follicular dendritic cell meshwork positive for CD21 was not observed. On the other hand, MALT lymphoma typically affects stomach, eyes, and ocular adnexa. In addition, in cases of MALT lymphoma and nodal marginal zone lymphoma, a follicular dendritic cell meshwork positive for CD21 is observed. Therefore, the present case was not compatible with typical MALT lymphoma and nodal marginal zone lymphoma. Additionally, extranodal infiltration in splenic marginal zone lymphoma is extremely rare; therefore, we did not consider it a likely diagnosis. Plasmacytoma typically presents as a localized proliferation of monoclonal plasma cells, without systemic IgM monoclonal gammopathy. Our patient, however, had a detectable serum IgM protein and bone marrow and skin infiltration by small to medium-sized lymphocytes, plasmacytoid lymphocytes, and plasma cells making plasmacytoma unlikely diagnosis. IgM multiple myeloma was also excluded diagnosis based on both clinical and laboratory findings. IgM multiple myeloma is usually accompanied by features such as lytic bone lesions, hypercalcemia, renal impairment, and significant anemia. In our case, PET-CT revealed no bone lesions, and laboratory tests showed a normal serum calcium level (8.9 mg/dL), preserved renal function (creatinine 0.7 mg/dL), and only mild anemia (hemoglobin 11.0 g/dL). Therefore, based on fulfillment of the diagnostic criteria for WM and the exclusion of other differential diagnoses, the diagnosis of WM was confirmed.Conclusions and Results (outcome and follow-up) : The patient met favorable prognostic criteria according to the Revised International Prognostic Scoring System for Waldenström’s Macroglobulinemia5); i.e., the patient’s age ≤65, β2-microglobulin >4 mg/L, LDH <250 IU/L, serum albumin level ≥3.5 g/dL, resulting in a total score of 1 point. Treatment with ibrutinib monotherapy was initiated by the internal medicine department. At the follow-up examination in our department two months after the introduction of ibrutinib, the palpable subcutaneous nodule in the right upper arm had regressed.Discussion: Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL) characterized by bone marrow infiltration of lymphoplasmacytic cells and the presence of serum monoclonal immunoglobulin M (IgM) [1-3]. It is a rare malignancy, accounting for only 1-2% of hematological malignancies.According to the World Health Organization classification [3], WM is characterized as a tumor composed of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells. This neoplasm typically involves the bone marrow, lymph nodes, and spleen. The definitive diagnosis requires the presence of bone marrow involvement by LPL and the detection of a monoclonal IgM gammopathy, irrespective of the concentration level. In our case, based on the presence of plasmacytoid lymphocytes, bone marrow infiltration, and monoclonal immunoglobulin M-kappa protein, a diagnosis of WM was made.While extramedullary involvement can occur in various organs, cutaneous manifestations are very rare, observed in approximately 5% of extramedullary WM cases [1]. Shakeri et al. classified the mechanisms of cutaneous manifestations in WM into primary and secondary types [4]; primary types are caused by tumor cell infiltration or IgM deposition and secondary types are caused by concurrent cryoglobulinemia. To the best of our knowledge, the previously reported cutaneous manifestations are papules, bullae, ulcerations, nodules and discoloration.Our case showed dense infiltration of plasmacytoid lymphocytes subcutaneously, indicating primary type of tumor cell infiltration. In a study by Stien et al. [2] reporting 19 cases of WM with cutaneous manifestations, 7 cases showed transformation to diffuse large B-cell lymphoma, while 12 cases did not. Among these 12 cases, nodular lesions were observed in 5 cases. Because i) cutaneous involvement occurs in few percentages of extramedullary WM cases and ii) cutaneous nodular lesion appears in only about half of these cases, the nodular lesions in this study are considered to be rare.In LPL, MYD88 L265P mutations are present in 90% of cases, and CXCR4 mutations occur in approximately 30% of cases [3]. Therefore, screening for these mutations is considered to contribute to a diagnosis. However, in our case, it was not possible to perform these mutation analyses. This limitation is acknowledged in the context of this case report. Nevertheless, since the MYD88 L265P mutation is not included in the diagnostic criteria, it is believed that this omission does not alter the diagnosis in the present case. Additionally, in situ hybridization was not performed to confirm light chain restriction. Instead, we assessed clonality using immunohistochemistry, which is the primary method employed in our routine diagnostic practice.Conclusion: Cutaneous manifestations of WM, particularly subcutaneous nodules, are rare but easily biopsied, suggesting that subcutaneous lesions may contribute to diagnosis. Therefore, dermatologists need to understand the cutaneous manifestations of WM.